Dr. Charles Nemeroff’s name is synonymous with what can go wrong when scientists who receive funding from the National Institutes of Health (NIH), the U.S. government’s $31 billion a year medical research arm, fail to disclose business relationships that pose a conflict of interest.
In 2008 came the embarrassing revelation that the prominent psychiatrist accepted nearly $1 million in consulting fees from Glaxo Smith Kline over six years while also leading NIH research on that same company’s antidepressant treatments. Nemeroff was also the chair of the psychiatry department at Emory University.
The NIH is trying to ...
(from the Open House Project blog)
As the research of the Harvard Transparency Policy Project has made abundantly clear, applying the principles of openness and transparency to complex systems demands a careful approach to epistemic nuances; questions like what should be knowable to whom need to be answered before disclosure requirements are implemented, and need to be built into a disclosure regime's initial design. (more)Continue reading